SpringWorks Therapeutics, Inc.
SWTXDrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Q2 2027
Market Overview
Stock performance and key metrics
1 upcoming, 1 past
Nirogacestat oral tablet
Desmoid Tumor
Mirdametinib (PD-0325901) oral capsule or dispersible tablet
Plexiform Neurofibroma
Nirogacestat
Ovarian Granulosa-Stromal Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Nirogacestat oral tablet | Phase 3 | Desmoid Tumor | - | - |
Mirdametinib (PD-0325901) oral capsule or dispersible tablet | Phase 2 | Plexiform Neurofibroma | - | - |
Nirogacestat | Phase 2 | Ovarian Granulosa-Stromal Tumor | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in SpringWorks Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in SpringWorks Therapeutics, Inc.'s (SWTX) pipeline across Phase 3, Phase 2. Its lead program is Nirogacestat oral tablet (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is SpringWorks Therapeutics, Inc.'s next FDA catalyst?→
SpringWorks Therapeutics, Inc.'s (SWTX) next tracked catalyst is a Phase 2 expected July 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SWTX biotech catalysts?→
Add SWTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow SpringWorks Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.